Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · IEX Real-Time Price · USD
140.55
-1.10 (-0.78%)
May 21, 2024, 4:00 PM EDT - Market closed
Neurocrine Biosciences Revenue
Neurocrine Biosciences had revenue of $1.98B in the twelve months ending March 31, 2024, with 23.99% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $515.30M with 22.57% year-over-year growth. In the year 2023, Neurocrine Biosciences had annual revenue of $1.89B with 26.76% growth.
Revenue (ttm)
$1.98B
Revenue Growth
+23.99%
P/S Ratio
7.22
Revenue / Employee
$1,415,714
Employees
1,400
Market Cap
14.14B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.89B | 398.40M | 26.76% |
Dec 31, 2022 | 1.49B | 355.20M | 31.34% |
Dec 31, 2021 | 1.13B | 87.60M | 8.38% |
Dec 31, 2020 | 1.05B | 257.80M | 32.71% |
Dec 31, 2019 | 788.10M | 336.90M | 74.67% |
Dec 31, 2018 | 451.20M | 289.57M | 179.16% |
Dec 31, 2017 | 161.63M | 146.63M | 977.51% |
Dec 31, 2016 | 15.00M | -4.77M | -24.12% |
Dec 31, 2015 | 19.77M | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 2.92M | -50.22M | -94.51% |
Dec 31, 2012 | 53.14M | -24.27M | -31.36% |
Dec 31, 2011 | 77.41M | 43.91M | 131.08% |
Dec 31, 2010 | 33.50M | 30.55M | 1,034.47% |
Dec 31, 2009 | 2.95M | -1.02M | -25.71% |
Dec 31, 2008 | 3.98M | 2.75M | 224.75% |
Dec 31, 2007 | 1.22M | -38.01M | -96.88% |
Dec 31, 2006 | 39.23M | -84.66M | -68.33% |
Dec 31, 2005 | 123.89M | 38.71M | 45.45% |
Dec 31, 2004 | 85.18M | -53.90M | -38.76% |
Dec 31, 2003 | 139.08M | 121.03M | 670.73% |
Dec 31, 2002 | 18.05M | -23.20M | -56.25% |
Dec 31, 2001 | 41.24M | 26.65M | 182.71% |
Dec 31, 2000 | 14.59M | -2.20M | -13.12% |
Dec 31, 1999 | 16.79M | 754.00K | 4.70% |
Dec 31, 1998 | 16.04M | -10.11M | -38.66% |
Dec 31, 1997 | 26.14M | 6.93M | 36.05% |
Dec 31, 1996 | 19.22M | 13.11M | 214.72% |
Dec 31, 1995 | 6.11M | 5.94M | 3,679.88% |
Dec 31, 1994 | 161.53K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Walgreens Boots Alliance | 144.60B |
Viatris | 15.36B |
Quest Diagnostics | 9.29B |
Illumina | 4.49B |
Hologic | 3.96B |
Revvity | 2.73B |
BioMarin Pharmaceutical | 2.47B |
Insulet | 1.78B |
NBIX News
- 32 minutes ago - Neurocrine Biosciences Announces Publication of Phase 3 KINECT®-4 Post Hoc Analysis Demonstrating Clinically Meaningful and Sustained Improvement in Tardive Dyskinesia With Long-Term Use of INGREZZA® (valbenazine) Capsules - PRNewsWire
- 7 days ago - Neurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024 - PRNewsWire
- 12 days ago - Neurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024 - PRNewsWire
- 12 days ago - Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy Adults - PRNewsWire
- 12 days ago - Nxera Pharma's partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults - GlobeNewsWire
- 13 days ago - Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults - PRNewsWire
- 14 days ago - Neurocrine Biosciences to Present at the BofA Securities 2024 Health Care Conference - PRNewsWire
- 14 days ago - Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024 - PRNewsWire